The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?

  title={The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?},
  author={Andrew D. Weeks},
  journal={BJOG: An International Journal of Obstetrics \& Gynaecology},
  pages={202 - 212}
  • A. Weeks
  • Published 1 January 2015
  • Medicine
  • BJOG: An International Journal of Obstetrics & Gynaecology
Postpartum haemorrhage (PPH) remains a major cause of maternal deaths worldwide, and is estimated to cause the death of a woman every 10 minutes. This review presents the latest clinical advice, including new evidence on controlled cord traction, misoprostol, and oxytocin. The controversy around the diagnosis of PPH, the limitations of universal prophylaxis, and novel ways to provide obstetric first aid are also presented. It ends with a call to develop high‐quality front‐line obstetric… 

Re: The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?

  • S. Matsubara
  • Medicine
    BJOG : an international journal of obstetrics and gynaecology
  • 2015
Sir, Weeks comprehensively described the present treatment trend of postpartum haemorrhage, concerning which Minicommentaries or Exchanges have been published one after another, indicating

Chapter 12: Improving Blood Transfusion Services

There are a number of barriers to the provision of transfusion services, especially in low- and middle-income settings where the need is the greatest, including unavailability of blood, unsafe blood, poor uptake of labour and delivery care, difficulties getting blood to transfusing facilities, and poor documentation of patient information.

Aetiology and treatment of severe postpartum haemorrhage.

An improved diagnosis of the causes of PPH especially retained placenta, together with an early recognition and treatment of coagulopathy, seem to be important in reducing severe PPH in an aim to minimize associated maternal morbidity.

Major obstetric hemorrhage management

The proposed algorithms, albeit not yet validated, are useful in the clinical practice; similarly beneficial is the use of reliable predictive panels such as the Modified Early Obstetric Warning System.

Postpartum Hysterectomy a Case Report of a Saving Life Surgery

Postpartum hemorrhage is the most cause of maternal mortality all over the world important and the latest professional apt to perform surgical procedures, such as B-Lynch surgery and the peripartum hysterectomy are needed.

Improving blood transfusion services.

  • T. TancredI. Bates
  • Medicine
    Best practice & research. Clinical obstetrics & gynaecology
  • 2019

To study the association of high risk factors and the postpartum hemorrhage at Tertiary Care Centre of Indore

It is hoped that this review paper increases the awareness of the various tamponade balloons and contributes to an evidencebased appraisal of its place in the management of PPH.

Carbetocin versus oxytocin for the prevention of postpartum haemorrhage during caesarean section-A study of 100 cases in Combined Military Hospital, Momenshahi

The main objective of this study is to find most crucial and effective drug of PPH prevention by comparing effectiveness of carbetocin vs. oxytocin.

Prophylactic uterotonics in the prevention of primary postpartum haemorrhage for unplanned out-of-hospital births: a literature review

The aim of this article is to review the use of uterotonic drugs used for the prevention of PPH which could be administered in out-of-hospital (OOH) births and to determine the efficacy of prophylactic uterotonics in reducing PPH within pre-hospital care.

Promptness of oxytocin administration for first-line treatment of postpartum hemorrhage: a national vignette-based study among midwives

This study using clinical vignettes showed delays in oxytocin administration for first-line treatment of PPH, and suggested that continuing training of midwives should be considered, especially in small maternity units.



Postpartum haemorrhage

While most women with postpartum blood loss less than 1000mL suffer no significant morbidity, the percentage of women who suffer a major PPH at the Women’s is comparable with local and international figures of 1-2%.

Prevention and Management of Postpartum Haemorrhage

These guidelines provide guidelines to help clinicians prevent and manage excessive bleeding postpartum and establish practices to facilitate the identification of women who may be at particularly high risk of PPH.

Carbetocin for preventing postpartum haemorrhage.

BACKGROUND Postpartum haemorrhage (PPH) is one of the major contributors to maternal mortality and morbidity worldwide. Active management of the third stage of labour has been proven to be effective

Postpartum misoprostol for preventing maternal mortality and morbidity.

To review maternal deaths and severe morbidity in all randomised trials of misoprostol for prevention or treatment of PPH, a large number of women will be needed to obtain robust estimates of maternal mortality, and cluster- and quasi-randomised trials are planned.

Tranexamic acid for preventing postpartum haemorrhage.

Tranexamic acid decreases postpartum blood loss after vaginal birth and after caesarean section based on two RCTs of unclear quality and further investigations are needed on efficacy and safety of this regimen for preventing PPH.

Variations in policies for management of the third stage of labour and the immediate management of postpartum haemorrhage in Europe

A survey of policies for management of the third stage of labour and immediate management of postpartum haemorrhage following vaginal birth in Europe and a review of attitudes, trial, and early warning system projects.

Prevention and treatment of postpartum hemorrhage in low‐resource settings

  • A. Lalonde
  • Medicine
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 2012

Prostaglandins for preventing postpartum haemorrhage.

Misoprostol orally or sublingually at a dose of 600 mcg shows promising results when compared to placebo in reducing blood loss after delivery and is preferable to conventional injectable uterotonics as part of the management of the third stage of labour especially for low-risk women.

Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage.

  • Dean LeducV. SenikasA. Lalonde
  • Medicine
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2009